MEDPACE HOLDINGS INC (MEDP) Stock Fundamental Analysis

NASDAQ:MEDP • US58506Q1094

451.76 USD
+4.67 (+1.04%)
At close: Feb 27, 2026
451.76 USD
0 (0%)
After Hours: 2/27/2026, 8:17:48 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Taking everything into account, MEDP scores 7 out of 10 in our fundamental rating. MEDP was compared to 57 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making MEDP a very profitable company, without any liquidiy or solvency issues. MEDP is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make MEDP suitable for growth and quality investing!


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year MEDP was profitable.
  • In the past year MEDP had a positive cash flow from operations.
  • MEDP had positive earnings in each of the past 5 years.
  • MEDP had a positive operating cash flow in each of the past 5 years.
MEDP Yearly Net Income VS EBIT VS OCF VS FCFMEDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • With an excellent Return On Assets value of 22.84%, MEDP belongs to the best of the industry, outperforming 98.25% of the companies in the same industry.
  • MEDP's Return On Equity of 98.27% is amongst the best of the industry. MEDP outperforms 100.00% of its industry peers.
  • MEDP's Return On Invested Capital of 71.19% is amongst the best of the industry. MEDP outperforms 100.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for MEDP is significantly above the industry average of 11.57%.
  • The last Return On Invested Capital (71.19%) for MEDP is above the 3 year average (49.20%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 22.84%
ROE 98.27%
ROIC 71.19%
ROA(3y)19.71%
ROA(5y)17.64%
ROE(3y)65.94%
ROE(5y)56.06%
ROIC(3y)49.2%
ROIC(5y)40.37%
MEDP Yearly ROA, ROE, ROICMEDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • With an excellent Profit Margin value of 17.83%, MEDP belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
  • MEDP's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 21.14%, MEDP belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
  • MEDP's Operating Margin has improved in the last couple of years.
  • MEDP has a Gross Margin of 30.06%. This is in the lower half of the industry: MEDP underperforms 73.68% of its industry peers.
  • MEDP's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 21.14%
PM (TTM) 17.83%
GM 30.06%
OM growth 3Y3.46%
OM growth 5Y3.23%
PM growth 3Y2.01%
PM growth 5Y2.64%
GM growth 3Y0.5%
GM growth 5Y-0.03%
MEDP Yearly Profit, Operating, Gross MarginsMEDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDP is creating value.
  • MEDP has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MEDP has been reduced compared to 5 years ago.
  • MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MEDP Yearly Shares OutstandingMEDP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
MEDP Yearly Total Debt VS Total AssetsMEDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 6.67 indicates that MEDP is not in any danger for bankruptcy at the moment.
  • MEDP has a better Altman-Z score (6.67) than 92.98% of its industry peers.
  • There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.67
ROIC/WACC6.62
WACC10.75%
MEDP Yearly LT Debt VS Equity VS FCFMEDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • MEDP has a Current Ratio of 0.74. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.74, MEDP is not doing good in the industry: 92.98% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.74 indicates that MEDP may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.74, MEDP is not doing good in the industry: 91.23% of the companies in the same industry are doing better.
  • MEDP does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.74
MEDP Yearly Current Assets VS Current LiabilitesMEDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • MEDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.14%, which is quite impressive.
  • The Earnings Per Share has been growing by 31.30% on average over the past years. This is a very strong growth
  • Looking at the last year, MEDP shows a quite strong growth in Revenue. The Revenue has grown by 19.97% in the last year.
  • Measured over the past years, MEDP shows a very strong growth in Revenue. The Revenue has been growing by 22.27% on average per year.
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y20.12%
Revenue growth 5Y22.27%
Sales Q2Q%32.03%

3.2 Future

  • Based on estimates for the next years, MEDP will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.29% on average per year.
  • The Revenue is expected to grow by 10.47% on average over the next years. This is quite good.
EPS Next Y9.87%
EPS Next 2Y10.52%
EPS Next 3Y10.19%
EPS Next 5Y10.29%
Revenue Next Year11.71%
Revenue Next 2Y9.56%
Revenue Next 3Y9.5%
Revenue Next 5Y10.47%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MEDP Yearly Revenue VS EstimatesMEDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
MEDP Yearly EPS VS EstimatesMEDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • MEDP is valuated quite expensively with a Price/Earnings ratio of 29.53.
  • MEDP's Price/Earnings ratio is a bit cheaper when compared to the industry. MEDP is cheaper than 64.91% of the companies in the same industry.
  • MEDP is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.07, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 26.87, MEDP can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MEDP indicates a somewhat cheap valuation: MEDP is cheaper than 66.67% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of MEDP to the average of the S&P500 Index (28.05), we can say MEDP is valued inline with the index average.
Industry RankSector Rank
PE 29.53
Fwd PE 26.87
MEDP Price Earnings VS Forward Price EarningsMEDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • MEDP's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. MEDP is cheaper than 66.67% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, MEDP is valued cheaply inside the industry as 85.96% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 18.66
EV/EBITDA 21.72
MEDP Per share dataMEDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of MEDP may justify a higher PE ratio.
PEG (NY)2.99
PEG (5Y)0.94
EPS Next 2Y10.52%
EPS Next 3Y10.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for MEDP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDPACE HOLDINGS INC

NASDAQ:MEDP (2/27/2026, 8:17:48 PM)

After market: 451.76 0 (0%)

451.76

+4.67 (+1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-09
Earnings (Next)04-20
Inst Owners87.1%
Inst Owner Change-2.2%
Ins Owners0.44%
Ins Owner Change-5.17%
Market Cap12.73B
Revenue(TTM)2.53B
Net Income(TTM)451.12M
Analysts52.22
Price Target497.46 (10.12%)
Short Float %5.92%
Short Ratio4.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.54%
Min EPS beat(2)7.52%
Max EPS beat(2)9.56%
EPS beat(4)4
Avg EPS beat(4)9.37%
Min EPS beat(4)2.57%
Max EPS beat(4)17.84%
EPS beat(8)8
Avg EPS beat(8)12.36%
EPS beat(12)11
Avg EPS beat(12)11.35%
EPS beat(16)15
Avg EPS beat(16)14.34%
Revenue beat(2)2
Avg Revenue beat(2)0.84%
Min Revenue beat(2)0.75%
Max Revenue beat(2)0.93%
Revenue beat(4)4
Avg Revenue beat(4)3.88%
Min Revenue beat(4)0.75%
Max Revenue beat(4)9.78%
Revenue beat(8)4
Avg Revenue beat(8)0.78%
Revenue beat(12)7
Avg Revenue beat(12)1.31%
Revenue beat(16)10
Avg Revenue beat(16)1.28%
PT rev (1m)-10.2%
PT rev (3m)-9.01%
EPS NQ rev (1m)1.41%
EPS NQ rev (3m)2.05%
EPS NY rev (1m)0%
EPS NY rev (3m)0.52%
Revenue NQ rev (1m)2.42%
Revenue NQ rev (3m)2.43%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE 29.53
Fwd PE 26.87
P/S 5.03
P/FCF 18.66
P/OCF 17.84
P/B 27.72
P/tB N/A
EV/EBITDA 21.72
EPS(TTM)15.3
EY3.39%
EPS(NY)16.81
Fwd EY3.72%
FCF(TTM)24.21
FCFY5.36%
OCF(TTM)25.32
OCFY5.6%
SpS89.82
BVpS16.3
TBVpS-8.4
PEG (NY)2.99
PEG (5Y)0.94
Graham Number74.9
Profitability
Industry RankSector Rank
ROA 22.84%
ROE 98.27%
ROCE 84.68%
ROIC 71.19%
ROICexc 333.94%
ROICexgc N/A
OM 21.14%
PM (TTM) 17.83%
GM 30.06%
FCFM 26.95%
ROA(3y)19.71%
ROA(5y)17.64%
ROE(3y)65.94%
ROE(5y)56.06%
ROIC(3y)49.2%
ROIC(5y)40.37%
ROICexc(3y)169.04%
ROICexc(5y)114.84%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)58.52%
ROCE(5y)48.87%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y101.11%
ROICexc growth 5Y74.12%
OM growth 3Y3.46%
OM growth 5Y3.23%
PM growth 3Y2.01%
PM growth 5Y2.64%
GM growth 3Y0.5%
GM growth 5Y-0.03%
F-Score7
Asset Turnover1.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 111.49%
Cap/Sales 1.24%
Interest Coverage 250
Cash Conversion 126.67%
Profit Quality 151.15%
Current Ratio 0.74
Quick Ratio 0.74
Altman-Z 6.67
F-Score7
WACC10.75%
ROIC/WACC6.62
Cap/Depr(3y)125.21%
Cap/Depr(5y)134.9%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.98%
Profit Quality(3y)144.35%
Profit Quality(5y)141.17%
High Growth Momentum
Growth
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
EPS Next Y9.87%
EPS Next 2Y10.52%
EPS Next 3Y10.19%
EPS Next 5Y10.29%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y20.12%
Revenue growth 5Y22.27%
Sales Q2Q%32.03%
Revenue Next Year11.71%
Revenue Next 2Y9.56%
Revenue Next 3Y9.5%
Revenue Next 5Y10.47%
EBIT growth 1Y19.71%
EBIT growth 3Y24.28%
EBIT growth 5Y26.22%
EBIT Next Year16.28%
EBIT Next 3Y12.32%
EBIT Next 5Y12.46%
FCF growth 1Y19.15%
FCF growth 3Y24.75%
FCF growth 5Y24.56%
OCF growth 1Y17.15%
OCF growth 3Y22.49%
OCF growth 5Y22.49%

MEDPACE HOLDINGS INC / MEDP FAQ

What is the fundamental rating for MEDP stock?

ChartMill assigns a fundamental rating of 7 / 10 to MEDP.


Can you provide the valuation status for MEDPACE HOLDINGS INC?

ChartMill assigns a valuation rating of 5 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.


What is the profitability of MEDP stock?

MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.


What are the PE and PB ratios of MEDPACE HOLDINGS INC (MEDP) stock?

The Price/Earnings (PE) ratio for MEDPACE HOLDINGS INC (MEDP) is 29.53 and the Price/Book (PB) ratio is 27.72.


How financially healthy is MEDPACE HOLDINGS INC?

The financial health rating of MEDPACE HOLDINGS INC (MEDP) is 8 / 10.